DE60304188D1 - Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT - Google Patents

Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT

Info

Publication number
DE60304188D1
DE60304188D1 DE60304188T DE60304188T DE60304188D1 DE 60304188 D1 DE60304188 D1 DE 60304188D1 DE 60304188 T DE60304188 T DE 60304188T DE 60304188 T DE60304188 T DE 60304188T DE 60304188 D1 DE60304188 D1 DE 60304188D1
Authority
DE
Germany
Prior art keywords
agents
hiüindolderivate
antipsychotic
against obesity
agents against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304188T
Other languages
English (en)
Other versions
DE60304188T2 (de
DE60304188T8 (de
Inventor
Hong Gao
Paul Stack
Louise Sabb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE60304188D1 publication Critical patent/DE60304188D1/de
Publication of DE60304188T2 publication Critical patent/DE60304188T2/de
Application granted granted Critical
Publication of DE60304188T8 publication Critical patent/DE60304188T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
DE60304188T 2002-04-25 2003-04-23 [1,4]diazocino[7,8,1-hi]indolderivate als antipsychotische mittel und mittel gegen obesität Active DE60304188T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37534902P 2002-04-25 2002-04-25
US375349P 2002-04-25
PCT/US2003/012691 WO2003091257A1 (en) 2002-04-25 2003-04-23 [1,4]DIAZOCINO [7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS

Publications (3)

Publication Number Publication Date
DE60304188D1 true DE60304188D1 (de) 2006-05-11
DE60304188T2 DE60304188T2 (de) 2006-12-28
DE60304188T8 DE60304188T8 (de) 2007-04-19

Family

ID=29270634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60304188T Active DE60304188T8 (de) 2002-04-25 2003-04-23 [1,4]diazocino[7,8,1-hi]indolderivate als antipsychotische mittel und mittel gegen obesität

Country Status (15)

Country Link
US (1) US7012089B2 (de)
EP (1) EP1497296B1 (de)
JP (1) JP4537076B2 (de)
CN (2) CN101003538A (de)
AR (1) AR039668A1 (de)
AT (1) ATE321050T1 (de)
AU (1) AU2003263119B2 (de)
BR (1) BR0309499A (de)
CA (1) CA2481324A1 (de)
DE (1) DE60304188T8 (de)
DK (1) DK1497296T3 (de)
ES (1) ES2260631T3 (de)
MX (1) MXPA04010373A (de)
TW (1) TW200307540A (de)
WO (1) WO2003091257A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
AR052227A1 (es) * 2004-11-05 2007-03-07 Wyeth Corp Metabolitos derivados de [1,4] diazepin [ 6,7,1-ij] quinolina, metodos de preparacion y usos de los mismos
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
AR060088A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
CA2644639A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
EP2742936A1 (de) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Kondensierte heterocyclische Verbindung und ihre Verwendung
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
EP2887804B1 (de) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indolen zur verwendung als glp-1 modulatoren
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2016123164A1 (en) 2015-01-29 2016-08-04 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
EP3733204A4 (de) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited Therapeutikum für belastungsinkontinenz und stuhlinkontinenz
WO2024118348A1 (en) * 2022-11-29 2024-06-06 Mirati Therapeutics, Inc. Processes and intermediates for synthesis of mrtx0902

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120463A (en) 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of 1,3-diazafluoranthene-1-oxide
US3417101A (en) 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
US4997831A (en) 1988-09-01 1991-03-05 Glaxo Group Limited Lactam derivatives
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
EP0882047A1 (de) 1996-02-21 1998-12-09 Darwin Discovery Limited Chinolone und ihre therapeutische verwendung
AU710825B2 (en) 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
JP2002518451A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド 環状アミノ酸化合物およびその医薬組成物、並びにそれら化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
CA2324474A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
KR20010108025A (ko) 1998-12-17 2001-12-07 이곤 이 버그 5ＨＴ2Ｃ 효능제인2,3,4,4ａ-테트라하이드로-1Ｈ-피라지노(1,2-ａ)퀴녹살린-5(6Ｈ)온 유도체
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
JP4762465B2 (ja) 1999-06-15 2011-08-31 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
CA2397349A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031201A1 (es) 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
WO2002036596A2 (en) * 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031198A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
WO2002042304A2 (en) 2000-11-03 2002-05-30 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists
EE200300303A (et) 2000-12-20 2003-12-15 Bristol-Myers Squibb Company Asendatud pürrolokinoliinid ja püridokinoliinid kui serotoniini agonistid ja antagonistid
HUP0303432A3 (en) 2000-12-20 2012-09-28 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
WO2003014125A1 (en) 2001-08-06 2003-02-20 Pharmacia & Upjohn Company Therapeutically useful tetracyclic ligands
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents

Also Published As

Publication number Publication date
ES2260631T3 (es) 2006-11-01
DK1497296T3 (da) 2006-06-06
EP1497296A1 (de) 2005-01-19
TW200307540A (en) 2003-12-16
US20040034005A1 (en) 2004-02-19
BR0309499A (pt) 2005-02-15
CN101003538A (zh) 2007-07-25
EP1497296B1 (de) 2006-03-22
AU2003263119A1 (en) 2003-11-10
CN1662539A (zh) 2005-08-31
ATE321050T1 (de) 2006-04-15
DE60304188T2 (de) 2006-12-28
JP2005531538A (ja) 2005-10-20
AU2003263119B2 (en) 2009-05-07
US7012089B2 (en) 2006-03-14
AR039668A1 (es) 2005-03-02
MXPA04010373A (es) 2005-02-03
CA2481324A1 (en) 2003-11-06
CN100376581C (zh) 2008-03-26
JP4537076B2 (ja) 2010-09-01
WO2003091257A1 (en) 2003-11-06
DE60304188T8 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
DE60304188D1 (de) Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60312838D1 (de) 1,2,3,4,7,8-HEXAHYDRO-6H-c1,4ÜDIAZEPINOc6,7,1-1JÜCHINOLINDERIVATIVE ALS ANTIPSYCHOTIKA UND MITTEL GEGEN OBESITAS
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
DE60326080D1 (en) Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE60221512D1 (de) Wabenstrukturkörper und anordnung dafür
ATE398127T1 (de) (1,4)diazepino(6,7,1-ij)chinolinderivate als antipsychotische und mittel gegen fettleibigkeit
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
DE60236099D1 (de) Druckverfahren, druckerzeugnisse und drucksteuerung
ATE338033T1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE60316445D1 (de) Funktionalisiertes polymer und verbesserte vulkanisate daraus
DE60237317D1 (de) Türsteuervorrichtung und aufzug
DE602004030044D1 (de) Bacillus thuringiensis und deren verwendungen
DE50211924D1 (de) Widerstandsschweisseinrichtung und steuerverfahren
DE60316588D1 (de) Neue lactame und deren verwendungen
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
ATE399542T1 (de) Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
DE60234388D1 (de) Therapeutische lotion gegen dermatitis
DE60335768D1 (de) Dichtungsanordnung und Gleitelement
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE10338270B4 (de) Variator und Variatoranordnung
DE60323517D1 (de) Hybridisierungsnachweisverfahren und bioassay-vorr
ATE538093T1 (de) Substituierte 2-carbonylamino-6- piperidinaminopyridine und substituierte 1- carbonylamino-3-piperidinaminobenzole als 5-ht1f- agonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition